Compounds kill C. diff, don't affect other gut bacteria in vitro

June 28, 2018 by Tracey Peake, North Carolina State University
Compounds kill C. diff, don’t affect other gut bacteria in vitro
C. diff. Credit: Renee Fox

NC State researchers developed a drug-testing pipeline to help identify compounds that worked against the three stages of Clostridium difficile infection, and found that a compound that holds promise for treating antibiotic-resistant bacteria may also be able to control C. difficile infections by killing the harmful bacteria without affecting other bacteria in the gut.

Clostridium difficile, or C. diff, is a bacterium that can cause painful and sometimes fatal infections: it is responsible for over 450,000 infections and 29,000 deaths annually in the United States. C. diff exists in the environment as a dormant spore. In a healthy gut other microbes within the gut keep C. diff in check. However, when the fail to keep C. diff in check; for example, when someone has taken antibiotics that kill off the "good" gut , the spores germinate, grow and produce toxins that damage the large intestine.

"The Catch-22 of C. diff is that the antibiotics that treat it exacerbate the problem by also eliminating bacteria that keep C. diff from growing," says Casey Theriot, an assistant professor of infectious disease at NC State. "So when we look for compounds that can be effective against C. diff, we have to look at a number of factors, including the compound's effect on the rest of gut microbiota."

Theriot and her team, led by Rajani Thanissery, created a small molecule pipeline that addressed those factors to help researchers identify compounds that could be used against C. diff.  The pipeline tested compounds against three different stages of the C. diff life cycle: growth, production and sporulation, as well as against other gut bacteria. The goal was to screen and select compounds that could inhibit one or all of the steps in the C. diff life cycle.

One of the small molecules she tested – 2-aminoimidazole (2-AI) – gave her some surprising results. 2-AI was developed by former NC State professors John Cavanagh and Christian Melander. The compound, derived from sea sponges, is effective against like MRSA. It works on these bacteria primarily by suppressing their ability to form biofilms or produce toxins, rather than killing the bacteria outright.

Thanissery screened eleven 2-AI molecules (compounds 1 through 11), provided by Daina Zeng and Raul Doyle at Agile Sciences, against C. diff in vitro. The molecules she screened were selected for their ability to inhibit C. diff growth, toxin activity and sporulation. Three molecules ( 1, 2, and 3) eliminated C. diff, but did not affect other bacteria. Compounds 4, 7, 9, and 11 inhibited toxin activity without affecting the growth of C. diff strains or the other microbiota.

"The results were both encouraging and surprising – we weren't expecting the molecules to kill C. diff, since they primarily inhibit virulence factors," Theriot says. "Our next steps will be to look more closely at the mechanisms by which 2-AI inhibits toxin activity.

"We were also pleased that our testing pipeline was able to successfully identify that demonstrated activity against different aspects of C. diff infection. Hopefully other researchers can use our pipeline to screen future therapeutics in the lab before moving into preclinical animal models."

The research appears in appears in Frontiers in Microbiology.

Explore further: A moveable feast: Antibiotics give C. diff a nutrient-rich environment, no competition

More information: Rajani Thanissery et al. A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against Clostridium difficile, Frontiers in Microbiology (2018). DOI: 10.3389/fmicb.2018.01206

Related Stories

A moveable feast: Antibiotics give C. diff a nutrient-rich environment, no competition

March 28, 2018
Using a mouse model, researchers from North Carolina State University have found that antibiotic use creates a "banquet" for Clostridium difficile (C. diff), by altering the native gut bacteria that would normally compete ...

Antibiotics pave way for C. diff infections by killing bile acid-altering bacteria

January 6, 2016
New research from North Carolina State University and the University of Michigan finds that bile acids which are altered by bacteria normally living in the large intestine inhibit the growth of Clostridium difficile, or C. ...

Bacterial in-fighting provides new treatment for hospital infections

September 6, 2017
A bacteria that is a leading cause of death worldwide from hospital acquired infections following antibiotic treatment looks set to be brought down through its own sibling rivalry.

New C. diff treatment reduces recurrent infections by 40 percent

January 25, 2017
A new treatment for Clostridium difficile (C.diff) infections reduces recurrent infections by nearly 40%, a large study has found.

Gastric medications increase risk for recurrence of Clostridium difficile infection

March 27, 2017
Researchers at Mayo Clinic have found patients who use gastric suppression medications are at a higher risk for recurrent Clostridium difficile (C-diff) infection. C-diff is a bacterium that can cause symptoms ranging from ...

C. diff study provides insight into antibiotic resistance and risks for infection

February 4, 2016
Exposure to specific antibiotics is linked to the development of certain strains of antibiotic-resistant C. difficile, one of the fastest growing bacteria superbugs, according to a new study published by Stuart Johnson, MD, ...

Recommended for you

New retinal ganglion cell subtypes emerge from single-cell RNA sequencing

July 18, 2018
Single-cell sequencing technologies are filling in fine details in the catalog of life. Researchers at the University of Connecticut Health Center (UConn Health) and The Jackson Laboratory (JAX) have identified 40 subtypes ...

Researchers develop novel bioengineering technique for personalized bone grafts

July 18, 2018
Scientists from the New York Stem Cell Foundation (NYSCF) Research Institute have developed a new bone engineering technique called Segmental Additive Tissue Engineering (SATE). The technique, described in a paper published ...

Fetal gene therapy prevents fatal neurodegenerative disease

July 16, 2018
A fatal neurodegenerative condition known as Gaucher disease can be prevented in mice following fetal gene therapy, finds a new study led by UCL, the KK Women's and Children's Hospital and National University Health System ...

New study finds that fat consumption is the only cause of weight gain

July 13, 2018
Scientists from the University of Aberdeen and the Chinese Academy of Sciences have undertaken the largest study of its kind looking at what components of diet—fat, carbohydrates or protein—caused mice to gain weight.

Basic research in fruit flies leads to potential drug for diseases afflicting millions

July 13, 2018
River blindness and elephantiasis are debilitating diseases caused by parasitic worms that infect as many as 150 million people worldwide. They are among the "neglected tropical diseases" for which better treatments are desperately ...

Light based cochlear implant restores hearing in gerbils

July 12, 2018
A team of researchers with members from a variety of institutions across Germany has developed a new type of cochlear implant—one based on light. In their paper published in the journal Science Translational Medicine, the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.